Trial
NCT02795819
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Virginia Commonwealth University
Collaborators
National Cancer Institute (NCI)
Condition
Renal Cell Carcinoma
Intervention
AR-42
Why stopped
Study drug no longer being clinically developed by manufacturer
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-10-24